Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 360

1.

A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

Hughes HR, Crill WD, Davis BS, Chang GJ.

Virology. 2012 Mar 15;424(2):129-37. doi: 10.1016/j.virol.2011.12.012. Epub 2012 Jan 14.

2.

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17.

PMID:
21596075
3.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
5.

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.

6.

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ.

J Infect Dis. 2007 Jun 1;195(11):1607-17. Epub 2007 Apr 17.

PMID:
17471430
7.

Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY.

J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9.

8.

Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.

Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, Cao H.

Vaccine. 2011 May 9;29(20):3695-702. doi: 10.1016/j.vaccine.2011.03.002. Epub 2011 Mar 17.

PMID:
21419774
9.

Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.

Long MT, Gibbs EP, Mellencamp MW, Bowen RA, Seino KK, Zhang S, Beachboard SE, Humphrey PP.

Equine Vet J. 2007 Nov;39(6):491-7.

PMID:
18065305
10.

A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.

El Garch H, Minke JM, Rehder J, Richard S, Edlund Toulemonde C, Dinic S, Andreoni C, Audonnet JC, Nordgren R, Juillard V.

Vet Immunol Immunopathol. 2008 Jun 15;123(3-4):230-9. doi: 10.1016/j.vetimm.2008.02.002. Epub 2008 Feb 16.

PMID:
18372050
11.

Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.

Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, Diamond MS, Hansen TH.

J Immunol. 2010 Apr 15;184(8):4423-30. doi: 10.4049/jimmunol.0903955. Epub 2010 Mar 8.

12.

Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.

Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD.

Vaccine. 2008 Jan 10;26(2):153-7. Epub 2007 Nov 20.

PMID:
18069096
13.

A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, Haagmans BL, Provacia LB, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2011 Apr 26;6(4):e18995. doi: 10.1371/journal.pone.0018995.

14.

Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.

Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J.

Expert Rev Vaccines. 2007 Apr;6(2):183-91. Review.

PMID:
17408368
15.

Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.

Chang GJ, Davis BS, Stringfield C, Lutz C.

Vaccine. 2007 Mar 8;25(12):2325-30. Epub 2006 Dec 5.

PMID:
17224209
16.

Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

Minke JM, Siger L, Cupillard L, Powers B, Bakonyi T, Boyum S, Nowotny N, Bowen R.

Vaccine. 2011 Jun 20;29(28):4608-12. doi: 10.1016/j.vaccine.2011.04.058. Epub 2011 May 5.

PMID:
21549780
17.

Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.

Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, Chouljenko VN, Baghian A, Apetrei C, Marx PA, Kousoulas KG.

Vaccine. 2009 Feb 5;27(6):893-903. doi: 10.1016/j.vaccine.2008.11.087. Epub 2008 Dec 12.

PMID:
19070640
18.

Rapid purification of recombinant dengue and West Nile virus envelope Domain III proteins by metal affinity membrane chromatography.

Tan LC, Chua AJ, Goh LS, Pua SM, Cheong YK, Ng ML.

Protein Expr Purif. 2010 Nov;74(1):129-37. doi: 10.1016/j.pep.2010.06.015. Epub 2010 Jul 1.

PMID:
20600950
19.

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN.

PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837. eCollection 2014. Erratum in: PLoS One. 2014;9(2):e91631.

20.

Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine.

Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M.

Vet Immunol Immunopathol. 2008 Dec 15;126(3-4):293-301. doi: 10.1016/j.vetimm.2008.08.007. Epub 2008 Aug 30.

PMID:
18838173

Supplemental Content

Support Center